Evidence map›Paper›PMID 34405542›Full record

ArticleClinical and translational science2021

An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.

Astrid De Meulenaere, Tijl Vermassen, David Creytens, Stijn De Keukeleire, Tim Delahaye, Philippe Deron, Fréderic Duprez, Samson Fung, Patrick Pauwels, Liesbeth Ferdinande and 1 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. [Chemical & biomedical imaging · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. The CD70-CD27 axis in oncology: the new kids on the block.Journal of experimental & clinical cancer research : CR · 2022
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Astrid De MeulenaereDepartment of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Tijl VermassenDepartment of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
David CreytensCancer Research Unit Ghent (CRIG), Ghent, Belgium.
Stijn De KeukeleireDepartment of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Tim Delahayeargenx B.V., Ghent, Belgium.
Philippe DeronDepartment Of Head and Neck Surgery, University Hospital Ghent, Ghent, Belgium.
Fréderic DuprezDepartment of Radiation Oncology, University Hospital Ghent, Ghent, Belgium.
Samson Fungargenx B.V., Ghent, Belgium.
Patrick PauwelsCentre for Oncological Research (CORE), University of Antwerp, and University Hospital Antwerp, Edegem, Belgium.
Liesbeth FerdinandeCancer Research Unit Ghent (CRIG), Ghent, Belgium.
Sylvie RotteyDepartment of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Ghent University Hospital · BECancer Research Institute Ghent · BEAntwerp University Hospital · BEArgenx (Belgium) · BEBH Consulting (Ireland) · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti-CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70

Indexed as

CD27 LigandAdultAgedAntibodies, MonoclonalAntineoplastic AgentsFeasibility StudiesFemaleHumansImmunologic FactorsMaleMiddle AgedNasopharyngeal CarcinomaYoung AdultAntibodies, MonoclonalAntineoplastic AgentsCD27 LigandCD70 protein, humanImmunologic Factors

Identifiers

PMID34405542
PMCPMC8604223
OpenAlexW3193920129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.